Revive Therapeutics Advances Psilocybin-Based Product Research

Revive Therapeutics (CSE: RVV) this morning announced that it has partnered with Complete Phytochemical Solutions for the purpose of advancing the firms research and development efforts of psilocybin-based products for the pharmaceutical market.

Complete Phytochemical is an internationally recognized firm that focuses on unique and complex analyses and formulation development of phytochemicals. The firm was formed in 2010 as a spin-off from the University of Wisconsin-Madison, with the firm currently operating out of the on-campus Reed Research Lab. Complete is lead by Christian G. Krueger and Dr Jess D. Reed, with the company having recently collaborated with Revive on development initiatives related to delivery vehicles for cannabinoids.

Revive has an intellectual property portfolio of psilocybin-based formulations ready to advance to the next stages of clinical development and with our newly-established relationship with Complete Phytochemical Solutions they will bring a wealth of product formulation and testing experience with phytochemicals, including hallucinogenics. Complete Phytochemical Solutions will be instrumental in achieving milestones that will unlock the potential of our psilocybin-based platform.

Michael Frank, Revive’s Chief Executive Officer

Revive currently has patent-pending methodology that includes psilocybin-based extraction and crystallization methodologies. Additionally, the company has filed for key provisional patent applications in the United States for methods of production of psilocybin-based formulations which includes sublingual and transmucosal delivery systems such as gum drops, oral strips, and dosing pens, as well as sublingual sprays, hard shell capsules, and effervescent tablets.

Revive Therapeutics last traded at $0.13 on the CSE.


FULL DISCLOSURE: Revive Therapeutics is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Revive Therapeutics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

3 Responses

  1. Any chance they can get some research done at the University of Wisconsin? I mean if they are already using a spin-off from the school, it kind of makes sense.

Video Articles

Gold Is Now Smart Money’s End Game | Doug Casey

Is Gold’s Bull Market About to Hit Junior Stocks? | Ken Armstrong – Westhaven Gold

Surge Battery Metals: The Nevada North Lithium PEA

Recommended

Goliath Resources Closes Out Funding Round With Total Gross Proceeds Of $27.1 Million

Silver47 Kickstarts 4,000 Metre Drill Campaign At Red Mountain Project

Related News

Revive Expects To Complete Phase 3 Interim Analysis In December On Bucillamine In Treatment of COVID-19

Revive Therapeutics (CSE: RVV) provided an update on the status of its ongoing phase three...

Monday, October 26, 2020, 10:54:38 AM

Revive Therapeutics Provides Update On Current Psilocybin Programs

Revive Therapeutics (CSE: RVV) this morning provided a corporate update as it pertains to its...

Tuesday, August 10, 2021, 08:36:06 AM

Revive Seeks To Advance Bucillamine Study To Phase 2 Clinical Study

This morning, Revive Therapeutics (CSE: RVV) released an update in relation to its ongoing study...

Monday, March 30, 2020, 08:31:03 AM

Revive Therapeutics Files For Patent On Oral Thin Film With Psilocybin

Revive Therapeutics (CSE: RVV) this morning announced that it has successfully completed research on an...

Thursday, April 22, 2021, 08:18:53 AM

PharmaTher, Revive, Complete Psilocybin Intellectual Property Transaction

PharmaTher (CSE: PHRM) has seen the completion of the sale of its psilocybin program to...

Wednesday, February 17, 2021, 09:58:18 AM